A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer

被引：36

作者：

Ji, Sang Hoon ^{[1
]}

Lim, Do Hyoung ^{[1
]}

Yi, Seong Yoon ^{[1
]}

Kim, Hyo Song ^{[1
]}

Jun, Hyun Jung ^{[1
]}

Kim, Kyoung Ha ^{[1
]}

Chang, Myung Hee ^{[1
]}

Park, Min Jae ^{[1
]}

Uhm, Ji Eun ^{[1
]}

Lee, Jeeyun ^{[1
]}

Park, Se Hoon ^{[1
]}

Park, Joon Oh ^{[1
]}

Park, Young Suk ^{[1
]}

Lim, Ho Yeong ^{[1
]}

Kang, Won Ki ^{[1
]}

机构：

[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul 135710, South Korea

来源：

BMC CANCER | 2009年 / 9卷

关键词：

GROWTH-FACTOR RECEPTOR; 1ST-LINE CHEMOTHERAPY; PROGNOSTIC-FACTOR; SUPPORTIVE CARE; PLUS; ADENOCARCINOMA; EXPRESSION; CISPLATIN; OUTCOMES; THERAPY;

D O I：

10.1186/1471-2407-9-110

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Because treatment of advanced gastric cancer (AGC) patients after failure with first-line chemotherapy remains controversial, we performed this retrospective analysis based on the data obtained from 1455 patients registered in a first-line treatment cohort with respect to receiving or not receiving subsequent chemotherapy. Methods: The decision for administering second-line chemotherapy was, in most cases, at the discretion of the physician. Seven-hundred twenty-five (50%) received second-line chemotherapy after first-line failure. Univariate and multivariate analyses were performed on the recognized baseline parameters for survival. Results: At the time of initiating second-line chemotherapy, the patients' median age was 56 years (range, 22 to 86) and 139 (19%) had an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or more. Seven (1%) complete and 108 (15%) partial responses to second-line chemotherapy were observed for an overall response rate of 16% (95% confidence interval [CI], 13 to 19%). The median progression-free and overall survivals, calculated from the start of second-line chemotherapy, were 2.9 months (95% CI, 2.6 to 3.3) and 6.7 months (95% CI, 5.8 to 7.5), respectively. Multivariate analysis revealed that low baseline hemoglobin level (hazard ratio [HR], 0.74; 95% CI 0.61-0.90) and a poor performance status (HR, 0.66; 95% CI, 0.52-0.83) were independent negative prognostic factors for overall survival. Conclusion: Performance status, along with baseline hemoglobin level, could be used to identify the subgroup of patients most likely to benefit from second-line chemotherapy for AGC.

引用

页数：6

共 17 条

[1]

Bae Jong Myon, 2002, Cancer Res Treat, V34, P77, DOI 10.4143/crt.2002.34.2.77

[2] Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data [J].